We focus on pragmatic Real-World Evidence (RWE) studies for generating clinically meaningful meaningful data and physician experience faster, unlocking the true potential of these transformational therapies sooner.
We believe it’s the best way to ensure rapid, safe and appropriate access to reimbursed psilocybin therapy.
Psilocybin-based medicines could change the way mental health is treated, and as a result, we believe the human experience as a whole will improve.
Current mental health treatments are decades old, relatively ineffective and can come with severe side effects. New approaches to antidepressants have failed, and major pharma has abandoned R&D in CNS research. 
Psilocybin therapy is a paradigm shift away from the traditional approaches such as antidepressants. It combines the pharmacological effects of psilocybin, a psychoactive substance, with psychological support.
Leading academics are demonstrating success with psilocybin as well as other psychoactive psychedelic medicines as therapy for treatment-resistant depression, anxiety, drug addiction and much more.
Albert Labs are conducting a rigorous, large-scale clinical development programme of KRN-101 psilocybin therapy for cancer related distress across the UK and Europe.
In these first preparation sessions, an Albert Labs therapist will get to know you closely and form a trusting relationship. The focus will be on establishing a therapeutic alliance between the therapist and participant.
During preparation, the therapist aims to build the participant’s capacity to navigate distressing experiences through self-directed enquiry and experiential processing. Practising this approach during preparation helps prepare the participant to engage with their experiences in the psilocybin session.
During the psilocybin session, the focus is on facilitating a meaningful experience. Patients listen to crafted music playlists and wear an eye mask. This helps the participant to focus internally. The psilocybin experience typically lasts 6-8 hours, and the participant is encouraged to maintain a courageous, trusting and open attitude in order to move “in and through” the full range of internal experiences. Albert Labs’ therapists maintain the same attitudes of openness and interest toward participants.
The therapeutic focus of integration is to reflect on the experience and generate insights following the psilocybin session. Participants are encouraged to describe and connect with the range of emotional, cognitive and physical experiences of the psilocybin session and relate them to their personal narratives. The integration process will generally unfold over time as the participant begins to implement changes in their life based on the experiences and insights of their psilocybin session.
– November 30, 2016
Stephen Ross, Anthony Bossis, Jeffrey Guss, Gabrielle Agin-Liebes, Tara Malone, Barry Cohen, Sarah E Mennenga, Alexander Belser, Krystallia Kalliontzi, James Babb, Zhe Su, Patricia Corby and Brian L Schmidt.
Roland R Griffiths, Matthew W Johnson1, Michael A Carducci, Annie Umbricht, William A Richards, Brian D Richards, Mary P Cosimano and Margaret A Klinedinst.
– September 6, 2010
Charles S Grob, Alicia L Danforth, Gurpreet S Chopra, Marycie Hagerty, Charles R McKay, Adam L Halberstadt, George R Greer.
© 2022 Albert Labs. All Rights Reserved
We are a pharmaceutical company leveraging our drug development and clinical research expertise to accelerate the development of highly effective mental health medicines.
If you would like support or more information around making an investment, please contact firstname.lastname@example.org